A possible new clue in pediatric cancer
Researchers in Norway have reported evidence that unusual antibodies may be involved in the development of some childhood cancers. The work focuses on autoantibodies: immune proteins that recognize the body’s own molecules rather than an outside threat.
In this case, the antibodies were directed at proteins used in DNA repair. DNA-repair machinery is a broad collection of proteins that identifies and corrects damage and mistakes in genetic material. The researchers found that children with several types of cancer had more antibodies against some of these proteins than comparison groups. They also reported that the autoantibodies could enter living cells and bind to the proteins they target.
The findings, published in Frontiers in Immunology, do not establish that the antibodies cause cancer. But they point to a potential mechanism worth investigating in a disease area where causes can differ sharply from those of cancers diagnosed later in life.
Why the question matters
Childhood cancers often emerge under different biological circumstances from adult cancers. Children have had far less time to accumulate DNA damage associated with aging, environmental exposures, and lifestyle factors. Pediatric tumors also tend to have fewer mutations and can arise from less mature cells, including stem or progenitor cells.
That makes it especially important to understand processes that could impair normal cellular safeguards early in life. DNA repair is one of those safeguards. If a repair protein cannot do its job, damage or errors in the genome may persist rather than being corrected.
The Norwegian team’s central observation is that children with pediatric cancers appeared to carry unusually high numbers of autoantibodies against components of that repair machinery. Corresponding author Ola Myklebost, an emeritus professor of molecular oncology at the University of Bergen, said the study also showed that such antibodies could enter live cells and bind to essential DNA-repair proteins. The researchers said this binding probably inhibits the proteins’ activity, though that question requires additional work.
What the researchers examined
The study analyzed the proteome, or full set of expressed proteins, in tumor and blood samples from 175 adults and children with sarcoma or acute lymphoblastic leukemia. The samples were collected between 2014 and 2017 through Norwegian research and hospital biobanks, including the NoSarC Norwegian Sarcoma Study, the Norwegian Childhood Cancer Biobank, and the Oslo University Hospital Cancer Research Biobank.
Those results were compared with samples from healthy anonymized participants. The comparison groups included blood donors as well as children involved in the Bergen Growth Study or visiting a clinic in Bergen.
According to the report, the strongest difference appeared among children aged 2 to 19 with pediatric cancer. Compared with young adults and older people, these children had substantially greater numbers of autoantibodies against DNA-repair proteins.
The cancers discussed in the report include leukemia, myeloma, neuroblastoma, and osteosarcoma, alongside the sarcoma and acute lymphoblastic leukemia samples used in the researchers’ characterization work. The finding is notable because it reaches across more than one pediatric cancer context, although it should not be interpreted as showing a single explanation for every childhood cancer.
Screening is a future possibility, not a present test
The researchers suggest that the observation could eventually inform early screening of young children. The idea is that identifying a concerning autoantibody pattern before disease develops might one day help researchers assess risk or explore preventive strategies.
That prospect remains preliminary. A screening program would need to show that the antibody signal reliably predicts meaningful outcomes, distinguishes risk from normal variation, and can be acted on safely. It would also need validation in larger and independent groups of children, as well as evidence about when the antibodies arise and how consistently they affect DNA repair in living tissue.
Still, the work offers a testable direction for pediatric oncology. Instead of looking only for inherited genetic changes or tumor mutations, researchers can ask whether an immune response is disrupting the systems that protect the genome. If that link is confirmed, it could broaden how clinicians and scientists think about cancer risk in children.
The next questions
- Do these autoantibodies precede cancer, or do they emerge as a consequence of disease?
- Which DNA-repair proteins are most important to the observed association?
- How often can the antibodies enter cells and materially reduce repair activity?
- Can the signal be replicated in larger, more diverse pediatric populations?
For now, the study is best viewed as evidence of a promising mechanism rather than a clinical conclusion. It adds an immune-system dimension to the search for why some childhood cancers arise and provides a specific hypothesis that can be tested in future studies.
This article is based on reporting by Medical Xpress. Read the original article.
Originally published on medicalxpress.com
